Brief: Journey Medical Corp Announces Topline Data From Phase 1 Clinical Trial Of DFD-29

Fortress Biotech

13/06/2023 15:12

June 13 (Reuters) - Journey Medical Corp  DERM.O :
    * JOURNEY MEDICAL CORPORATION ANNOUNCES POSITIVE TOPLINE
DATA FROM
PHASE 1 CLINICAL TRIAL ASSESSING THE IMPACT OF DFD-29
(MINOCYCLINE HYDROCHLORIDE MODIFIED RELEASE CAPSULES, 40 MG) ON
MICROBIAL FLORA OF HEALTHY ADULT SUBJECTS
    * JOURNEY MEDICAL CORP - CLINICAL TRIAL ACHIEVED ALL THREE
PRIMARY
OBJECTIVES AND SUBJECTS COMPLETED 16-WEEK TREATMENT WITH NO
SIGNIFICANT SAFETY ISSUES
    * JOURNEY MEDICAL CORP - TOPLINE DATA FROM PHASE 3 CLINICAL
TRIALS
ARE ANTICIPATED IN JUNE 2023
    * JOURNEY MEDICAL CORP - NEW DRUG APPLICATION FILING
SUBSEQUENTLY
EXPECTED IN SECOND HALF OF 2023

Source text for Eikon:  ID:nGNX3f7hXk 
Further company coverage:  DERM.O 

 (reuters.briefs@thomsonreuters.com)